Quotient Therapeutics Appoints Andrew (Andy) Bayliffe, Ph.D. As Chief Development Officer To Drive Somatic Genomics-Based Drug Development

Quotient Therapeutics, a company pioneering somatic genomics to advance the development of breakthrough medicines, has announced the appointment of Andrew (Andy) Bayliffe, Ph.D., as Chief Development Officer. Dr. Bayliffe brings more than 25 years of leadership in the biopharmaceutical industry, with extensive expertise in the discovery and development of small-molecule and antibody therapeutics across multiple disease areas.

Dr. Bayliffe’s career spans experience in pharmaceutical, biotechnology, and venture capital settings. He spent two decades at GlaxoSmithKline Pharmaceuticals, where he played a central role in guiding the discovery and development of numerous drug programs across both early- and late-stage clinical phases. His work during this time helped establish deep expertise in the clinical pharmacology of both small and large molecules.

Rahul Kakkar, MD, Chief Executive Officer of Quotient, stated, “Andy brings a depth of drug development expertise across modalities and therapeutic areas, joining at a pivotal time as we look to translate our somatic genomics findings into meaningful medicines for patients. His leadership will be instrumental in executing on our internal and partnered programs, and we are delighted to welcome him to the team.” 

Andy Bayliffe, PhD also added, “Through the discovery of novel drug targets, Quotient has a unique opportunity to transform standards of care across a broad spectrum of diseases. I look forward to joining this innovative team and ensuring our Somatic Genomics technology enables the development of treatments for patients in need.”

Following his tenure at GSK, Dr. Bayliffe became a Venture Partner at Apple Tree Partners, a venture capital firm. There, he co-founded Marengo Therapeutics and served as Chief Scientific Officer. In that role, he led the discovery of several novel T-cell receptor (TCR)-targeted antibody platforms for the treatment of autoimmune and oncology diseases. Over his more than five years as CSO, he advanced a diverse pipeline of wholly owned and partnered programs while defining the translational pharmacology of lead molecules that progressed into Phase 1/2 clinical trials.

Dr. Bayliffe has also built a strong track record of collaboration with academic researchers, clinical leaders, funding organizations, and regulatory agencies. His contributions extend beyond his leadership roles, as he continues to publish original research in peer-reviewed journals and remains actively involved in the field of translational science and experimental medicine through participation in learned societies and scientific institutions. He earned his undergraduate and doctoral degrees in pharmacology, physiology, and molecular biology from Manchester Metropolitan University and Leeds University in the United Kingdom.